Environment and Lung Cancer

NCT05119244 | Recruiting

• 1 other identifier: 2021-A02062-39
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 3

Brief Summary

Cannabis is the most consumed drug in the world and the French are the main consumers in Europe. The most recognized effects of cannabis on human health are of a neuro-psychic nature. The medical literature on the effects of cannabis on the lung in general, and on lung carcinogenesis in particular, is most often reassuring (Tashkin, Chest 2018; Zhang, Int J Cancer 2015; Ghasemiesfe JAMA Netw. Open. 2019), despite the fact that the concentration of carcinogens in cannabis smoke is higher than that contained in tobacco smoke (Moir, Chem. Res. Toxicol. 2008), and that cannabis smoking has been implicated in the occurrence of ENT cancers. Rather, research focuses on the therapeutic effects of cannabis, especially analgesics, and even on its possible anti-tumor virtues (Abrams, Jama Oncol. 2020). These reassuring data should, however, be viewed with a great deal of caution. On the one hand, the illegal nature of cannabis in most countries and its frequent association with tobacco consumption make studies on the subject difficult and often biased. On the other hand, the daily practice of oncologists, who observe numerous cases of advanced and rapidly progressive lung cancer occurring in young patients who are heavy users of cannabis, raises suspicion of an unrecognized role of cannabis in lung carcinogenesis. In a preliminary multicenter study on French patients under 50 years of age operated for primary lung cancer (Betser, ERJ 2021), we demonstrated that cannabis consumption was extremely frequent, concerning 43% of patients, but mentioned in patients' medical records only in 4 out of 10 cases, while the smoking status was always noted. In addition, by comparing people who smoke cannabis (always here associated with tobacco) to patients who only smoke tobacco or to non-smokers, we identified a different profile of lung cancers, with more poorly differentiated tumors, presenting at a more advanced stage (more T3-T4 versus T1-T2) requiring more complex surgery, and mostly located in the upper lobes of the lung. Similar research work is currently underway at Gustave Roussy (Dr Pradere-Dr Planchard, Villejuif, France) on patients with metastatic lung cancer, with a focus on overall survival and molecular profile.

Conditions

Cannabis Use

Keywords

Cannabis, Lung Cancer

Outcome Measures

Primary Outcomes (1)

• percentage of patients who are active or not active cannabis smokers (at least 10 joints per for at least one year).

  1 year

Study Arms (3)

cannabis smokers

EXPERIMENTAL

Other: blood and hair sampling

Tobacco smokers

EXPERIMENTAL

Other: blood and hair sampling

Non-smoking patients

EXPERIMENTAL

Other: blood and hair sampling

Interventions

blood and hair sampling OTHER

3.5 ml blood sample Hair sample

Non-smoking patients; Tobacco smokers; cannabis smokers

Eligibility Criteria

• Age: 18 Years - 59 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Any patient from 18 y.o to 59 y.o treated in one of the three above-mentioned hospitals for primary lung cancer, whatever its stage, and agreeing to participate in this research.

You may not qualify if:

• Patient denied participation.

Sponsors & Collaborators

• Centre Chirurgical Marie Lannelongue: lead

Study Sites (3)

Centre Chirurgical Marie Lannelongue

Le Plessis-Robinson, 92350, France

RECRUITING

Hopital Paris Saint Joseph

Paris, 75014, France

COMPLETED

Institut Gustave Roussy

Villejuif, France

COMPLETED

MeSH Terms

Conditions

Marijuana Abuse; Lung Neoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Pauline PRADERE, MD

CONTACT

01.40.94.22.79; p.pradere@ghpsj.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 2, 2021
• First Posted: November 15, 2021
• Study Start: October 1, 2021
• Primary Completion: October 1, 2022
• Study Completion (Estimated): February 1, 2027
• Last Updated: May 6, 2026

Record last verified: 2026-04

Locations

FR (3)